TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28683766

Group type: EXPERIMENTAL
Intervention: ixazomib-Rd
Number of subjects: 115

Group type: COMPARATOR
Intervention: placebo-Rd
Number of subjects: 115
Study: 25577471

Group type: EXPERIMENTAL
Intervention: DiAlert intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 22841396

Group type: EXPERIMENTAL
Intervention: γ‐TmT supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no γ‐TmT supplementation)
Number of subjects: 15
Study: 21726916

Group type: EXPERIMENTAL
Intervention: pioglitazone-metformin
Number of subjects: 68

Group type: COMPARATOR
Intervention: glimepiride-metformin
Number of subjects: 68
Study: 18653426

Group type: EXPERIMENTAL
Intervention: Educational intervention (n = 22)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No intervention (n = 21)
Number of subjects: 80
Study: 17126774

Group type: EXPERIMENTAL
Intervention: Propofol (Diprifusor) target-controlled infusion at a predetermined target concentration starting at 2.5 mug/mL; step size of 0.1 microg/mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol (Diprifusor) target-controlled infusion
Number of subjects: 50
Study: 14559317

Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 fatty acids (4.5 g/d) + sulfasalazine (2 g/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sulfasalazine (2 g/d) alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 9
Study: 10812331

Group type: EXPERIMENTAL
Intervention: UV radiation (UVR) exposure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin type I and II
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Photoproduct repair rates at 24 h and 48 h after UV irradiation
Number of subjects: 30
Study: 8857137

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 33
Study: 1509401

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF (50 micrograms/m2)
Number of subjects: 6
Study: 6374866

Group type: EXPERIMENTAL
Intervention: Oxmetidine 400 mg twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cimetidine 1 g daily
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 101
Study: 31816478

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC)
Number of subjects: 71
Study: 30852132

Group type: EXPERIMENTAL
Intervention: Integrated structured weight-management programme
Number of subjects: 149

Group type: COMPARATOR
Intervention: Best-practice care
Number of subjects: 149
Study: 30007359

Group type: EXPERIMENTAL
Intervention: Loneliness measured by CES-D
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Loneliness measured by UCLA Loneliness Scale
Number of subjects: 254
Study: 27670851

Group type: EXPERIMENTAL
Intervention: 30 shocks/min
Number of subjects: 160

Group type: COMPARATOR
Intervention: 60 shocks/min
Number of subjects: 160
Study: 23314489

Group type: EXPERIMENTAL
Intervention: 12 daily local mud packs and generalized thermal baths with sulfate‐calcium‐magnesium‐fluorides mineral water added to usual treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular outpatient care routine (exercise, NSAIDs and/or analgesics)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12 daily local mud packs and generalized thermal baths
Number of subjects: 60
Study: 22170369

Group type: EXPERIMENTAL
Intervention: 60 g WG/d for 16 wk
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 60 g WG/d for 8 wk followed by 120 g WG/d for 8 wk
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control (no dietary change)
Number of subjects: 316
Study: 21126610

Group type: EXPERIMENTAL
Intervention: PPCI with enoxaparin and abciximab
Number of subjects: 205

Group type: COMPARATOR
Intervention: Thrombolysis with enoxaparin and reteplase
Number of subjects: 205
Study: 17703184

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 41
Study: 15786932

Group type: EXPERIMENTAL
Intervention: PADMA 28, 3 x 2 capsules daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12040291

Group type: EXPERIMENTAL
Intervention: G-CSF administration at 7:00 am
Number of subjects: 20

Group type: COMPARATOR
Intervention: G-CSF administration at 7:00 pm
Number of subjects: 20
Study: 10341401

Group type: EXPERIMENTAL
Intervention: Ultrasound during pregnancy
Number of subjects: 4715

Group type: EXPERIMENTAL
Intervention: Ultrasound during pregnancy (subgroup analysis among boys)
Number of subjects: 4715

Group type: EXPERIMENTAL
Intervention: Exploratory analyses (exposure vs non-exposure)
Number of subjects: 4715

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 4715
Study: 8543487

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg tds
Number of subjects: 864

Group type: COMPARATOR
Intervention: Ceftazidime 500 mg tds
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg bd
Number of subjects: 864

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg bd
Number of subjects: 864

Group type: COMPARATOR
Intervention: Ceftazidime 1 g tds
Number of subjects: 864
Study: 1962599

Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg once daily
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg once daily
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg once daily
Number of subjects: 254
Study: 7046782

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline 7.5 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ordinary terbutaline 5 mg three times daily
Number of subjects: 20
Study: 31953730

Group type: EXPERIMENTAL
Intervention: Trained group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trained females
Number of subjects: 32

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 32
Study: 29304772

Group type: EXPERIMENTAL
Intervention: Intervention group (EDAl program)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study: 26651453

Group type: EXPERIMENTAL
Intervention: Bosentan for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 25580717

Group type: EXPERIMENTAL
Intervention: Self-affirmation task
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 110
Study: 23579367

Group type: EXPERIMENTAL
Intervention: GC1107‐T5.0
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: GC1107‐T7.5
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All groups (GC1107‐T5.0, GC1107‐T7.5, Control)
Number of subjects: 130
Study: 19680279

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (Avastin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other treatment options (control group)
Number of subjects: 0
Study: 18004683

Group type: EXPERIMENTAL
Intervention: 0.3 g.kg(‐1) BW NaHCO3 ingestion with passive recovery (BICARB P)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.3 g.kg(‐1) BW NaHCO3 ingestion with active recovery (BICARB A)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ingestion with passive recovery (PLAC P)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ingestion with active recovery (PLAC A)
Number of subjects: 9
Study: 16421365

Group type: EXPERIMENTAL
Intervention: Inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily without amiloride pretreatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inhaled hypertonic saline with amiloride pretreatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled hypertonic saline with placebo
Number of subjects: 24
Study: 15556830

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg and 25 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib (200 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen (4000 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nabumetone (1000 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg)
Number of subjects: 0
Study: 11475497

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study: 8940983

Group type: EXPERIMENTAL
Intervention: PRP-T
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: PRP-OMP
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 1307884

Group type: EXPERIMENTAL
Intervention: Ocean sounds played on the Marsona Sound Conditioner for three consecutive nights posttransfer from the ICU
Number of subjects: 60

Group type: COMPARATOR
Intervention: No control of environment, except for the elimination of white noise
Number of subjects: 60
Study: 3877303

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg bolus injection over 5 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol 2 mg/kg bolus injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg and 2.0 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol infusion for maintenance of anaesthesia
Number of subjects: 60
Study: 2887153

Group type: EXPERIMENTAL
Intervention: Topical 1% ALO 2145
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 30102965

Group type: EXPERIMENTAL
Intervention: 30 mg of toreforant once daily through week 24
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 25773049

Group type: EXPERIMENTAL
Intervention: State mandates for coverage of colorectal, cervical, and prostate cancer screenings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coverage of preventive care (mandated or not)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Users of cancer screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-users of cancer screening
Number of subjects: 0
Study: 24901463

Group type: EXPERIMENTAL
Intervention: Announced pill count
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: PACTG adherence questionnaire
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Child self‐report
Number of subjects: 207
Study: 22414520

Group type: EXPERIMENTAL
Intervention: Tetracaine anesthetic paste (TAP) applied to the maxillary mucobuccal fold
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzocaine paste applied to the opposite side
Number of subjects: 0
Study: 20731494

Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program treatment group
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 461
Study: 19035431

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 15671258

Group type: EXPERIMENTAL
Intervention: Active intervention (vitamin supplementation)
Number of subjects: 4060
Study: 12759558

Group type: EXPERIMENTAL
Intervention: Open-label nortriptyline (NT) treatment for 6 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Baseline cholesterol levels
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fluoxetine treatment for 8 weeks (control group)
Number of subjects: 92
Study: 10698385

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide 20 ppm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide 40 ppm
Number of subjects: 45
Study: 9114142

Group type: EXPERIMENTAL
Intervention: Stibogluconate + Allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stibogluconate
Number of subjects: 0
Study: 8240434

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2870222

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg three times a day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg twice a day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Withdrawal of verapamil
Number of subjects: 6
Study: 31213227

Group type: EXPERIMENTAL
Intervention: Multiple exemplar condition
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low-word overlap condition
Number of subjects: 132

Group type: COMPARATOR
Intervention: High-word overlap condition
Number of subjects: 132
Study: 29439994

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 27260196

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 199
Study: 24140220

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous antibiotics
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1640
Study: 22569086

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 569

Group type: COMPARATOR
Intervention: Iron‐folic acid supplementation
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study: 20536364

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 170
Study: 17490928

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg daily for 12 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glipizide (10 mg daily for 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (subjects without diabetes)
Number of subjects: 19
Study: 16198879

Group type: EXPERIMENTAL
Intervention: Real-time 3D Doppler echocardiography
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2-dimensional echocardiography
Number of subjects: 50
Study: 11833827

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 to 300 mg/d
Number of subjects: 238

Group type: COMPARATOR
Intervention: Enalapril 10 to 20 mg/d
Number of subjects: 238
Study: 11109752

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 50
Study: 8625624

Group type: EXPERIMENTAL
Intervention: 10% low‐molecular‐weight hydroxyethyl starch solution
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 20% human albumin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous administration of pentoxifylline (1.4 mg/kg/hr iv)
Number of subjects: 42
Study: 1526697

Group type: EXPERIMENTAL
Intervention: Dihydroergocryptine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31056081

Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse bitemporal ECT (3 times seizure threshold)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Brief pulse bitemporal ECT (1.5 times seizure threshold)
Number of subjects: 36
Study: 31237107

Group type: EXPERIMENTAL
Intervention: Auditory-cognitive training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Documentary videos (Control)
Number of subjects: 76
Study: 29070639

Group type: EXPERIMENTAL
Intervention: 3-month workplace intervention programme with environmental changes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving three times feedback of the assessment of physical activity and basic occupational health service
Number of subjects: 0
Study: 26184841

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24135509

Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 432

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 432
Study: 21892106

Group type: EXPERIMENTAL
Intervention: Arm A: 40 Gy/20 fractions/4 weeks with concurrent weekly vinorelbine 25 mg/m + cisplatin 20 mg/m
Number of subjects: 84

Group type: COMPARATOR
Intervention: Arm B: 30 Gy/15 fractions/3 weeks with concurrent weekly gemcitabine 200 mg
Number of subjects: 84
Study: 19393989

Group type: EXPERIMENTAL
Intervention: Oral alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17043069

Group type: EXPERIMENTAL
Intervention: Automatic mode switching (AMS) of pacemakers
Number of subjects: 57
Study: 12775784

Group type: EXPERIMENTAL
Intervention: Health education and physical exercise programme (8 sessions of 2 hours each)
Number of subjects: 126
Study: 10689005

Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg vaginally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prometrium (100 mg orally)
Number of subjects: 12
Study: 9034811

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study: 8480507

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 27
Study: 3688071

Group type: EXPERIMENTAL
Intervention: Breast stimulation test
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oxytocin challenge test
Number of subjects: 50
Study: 28920756

Group type: EXPERIMENTAL
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 27229736

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=26): twice weekly 60-min group exercise classes, at least 3 days/week self-directed exercise, daily pedometer, weekly telephone counseling
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care control (n=25)
Number of subjects: 51
Study: 26403206

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided femoral nerve block (FNB) with 20 mL of 0.5% bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided femoral nerve block (FNB)
Number of subjects: 50
Study: 23901023

Group type: EXPERIMENTAL
Intervention: EGCG-rich green tea extract (300-900 mg/day)
Number of subjects: 0
Study: 20948453

Group type: EXPERIMENTAL
Intervention: HibMenCY‐TT
Number of subjects: 1104
Study: 18303408

Group type: EXPERIMENTAL
Intervention: Neoadjuvant platinum/taxanes chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Surgery (radical hystero-oophorectomy, omentectomy, lymphadenectomy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FPDNA levels above cutoff after chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FPDNA levels below cutoff after chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FPDNA levels above and below cutoff
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy blood donor volunteers
Number of subjects: 22
Study: 16569962

Group type: EXPERIMENTAL
Intervention: Titanium membrane with autologous bone graft (test group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Titanium membrane without autologous bone graft (control group)
Number of subjects: 10
Study: 15189588

Group type: EXPERIMENTAL
Intervention: Culturally instilled folk theories (Asian-primed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culturally instilled folk theories (American-primed)
Number of subjects: 0
Study: 10961518

Group type: EXPERIMENTAL
Intervention: 10 mg oral montelukast
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9174478

Group type: EXPERIMENTAL
Intervention: Calcium intake of 684 mg/d (baseline)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reduced calcium intake (280 mg/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Increased calcium intake (1281 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (baseline calcium intake)
Number of subjects: 14
Study: 7721145

Group type: EXPERIMENTAL
Intervention: Exposure to chemical disinfectants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hygienic prophylactic recommendations
Number of subjects: 0
Study: 2595747

Group type: EXPERIMENTAL
Intervention: Terodiline (25 mg b.i.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10940

Group type: EXPERIMENTAL
Intervention: Rimiterol (0.5 mug kg‐1 min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rimiterol (0.05 mug kg‐1 min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.3 mug kg‐1 min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.03 mug kg‐1 min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.05 mug kg‐1 min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.005 mug kg‐1 min‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31427252

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (45 mg/kg per day)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg per day)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 28624576

Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 25933358

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1308
Study: 25024070

Group type: EXPERIMENTAL
Intervention: T-DM1 3.6 mg/kg every 3 weeks
Number of subjects: 884
Study: 22967970

Group type: EXPERIMENTAL
Intervention: salvia miltiorrhiza and ligustrazine injection (250 mL glucose injection containing 10 mL concoction, once a day for three days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: routine treatment methods (fluid resuscitation, anti‐infection treatment, support treatment, organ‐protection treatment)
Number of subjects: 20
Study: 19533762

Group type: EXPERIMENTAL
Intervention: Intra-gastric violet light phototherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (standard antibiotic treatment)
Number of subjects: 18
Study: 17696983

Group type: EXPERIMENTAL
Intervention: Immediate ultrasound training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed ultrasound training (wait-list control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard instruction on abdominal examination
Number of subjects: 0